Elicio Therapeutics Inc (ELTX)
10.01
+0.63
(+6.72%)
USD |
NASDAQ |
May 17, 16:00
10.01
0.00 (0.00%)
After-Hours: 19:04
Elicio Therapeutics Enterprise Value: 82.98M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 82.98M |
| May 15, 2024 | 93.40M |
| May 14, 2024 | 92.38M |
| May 13, 2024 | 85.74M |
| May 10, 2024 | 83.29M |
| May 09, 2024 | 84.21M |
| May 08, 2024 | 82.67M |
| May 07, 2024 | 79.61M |
| May 06, 2024 | 78.89M |
| May 03, 2024 | 78.89M |
| May 02, 2024 | 79.10M |
| May 01, 2024 | 77.56M |
| April 30, 2024 | 81.14M |
| April 29, 2024 | 80.12M |
| April 26, 2024 | 78.99M |
| April 25, 2024 | 80.12M |
| April 24, 2024 | 81.65M |
| April 23, 2024 | 81.34M |
| April 22, 2024 | 86.66M |
| April 19, 2024 | 72.96M |
| April 18, 2024 | 71.22M |
| April 17, 2024 | 82.16M |
| April 16, 2024 | 85.53M |
| April 15, 2024 | 81.45M |
| April 12, 2024 | 87.78M |
| Date | Value |
|---|---|
| April 11, 2024 | 88.19M |
| April 10, 2024 | 76.74M |
| April 09, 2024 | 77.05M |
| April 08, 2024 | 75.62M |
| April 05, 2024 | 77.56M |
| April 04, 2024 | 63.97M |
| April 03, 2024 | 62.43M |
| April 02, 2024 | 62.95M |
| April 01, 2024 | 59.88M |
| March 28, 2024 | 64.79M |
| March 27, 2024 | 63.35M |
| March 26, 2024 | 59.68M |
| March 25, 2024 | 57.63M |
| March 22, 2024 | 56.81M |
| March 21, 2024 | 54.56M |
| March 20, 2024 | 54.56M |
| March 19, 2024 | 52.21M |
| March 18, 2024 | 52.52M |
| March 15, 2024 | 35.12M |
| March 14, 2024 | 37.43M |
| March 13, 2024 | 36.08M |
| March 12, 2024 | 39.73M |
| March 11, 2024 | 39.83M |
| March 08, 2024 | 34.36M |
| March 07, 2024 | 30.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
18.80M
Minimum
Jan 24 2024
152.29M
Maximum
Jun 02 2023
54.78M
Average
50.96M
Median
Sep 20 2023
Enterprise Value Benchmarks
| Immuneering Corp | -25.61M |
| Outlook Therapeutics Inc | 184.40M |
| Amylyx Pharmaceuticals Inc | -248.84M |
| NovaBay Pharmaceuticals Inc | 5.209M |
| Palatin Technologies Inc | 23.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.949M |
| Total Expenses (Quarterly) | 9.392M |
| EPS Diluted (Quarterly) | -0.9318 |
| Earnings Yield | -255.6% |